Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its impl

scientific article published in December 2007

Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its impl is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.2007.12.8033
P698PubMed publication ID18048824
P5875ResearchGate publication ID5798846

P50authorAmerican Society of Clinical OncologyQ2843019
College of American PathologistsQ5146628
P2093author name stringDavid L Rimm
David Huntsman
Annette Molinaro
Malini Harigopal
Robert L Camp
Christopher B Moeder
Andrew Robinson
Karen Gelmon
Jennifer M Giltnane
P433issue34
P407language of work or nameEnglishQ1860
P921main subjectErb-b2 receptor tyrosine kinase 2Q415271
P304page(s)5418-5425
P577publication date2007-12-01
P1433published inJournal of Clinical OncologyQ400292
P1476titleQuantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its impl
P478volume25